Riboflavin’s next commercial chapter may not be about increasing the dose, but changing its destination. Vitamin B2 is essential for human metabolism and also supports several microbial functions. Yet conventional oral riboflavin is largely absorbed in the small intestine, meaning that only a limited proportion reaches the colon, where most of the gut microbiota resides.

Humiome® B2, developed by dsm-firmenich, has been designed to address this delivery gap. The ingredient uses a patented coating technology intended to transport riboflavin through the upper gastrointestinal tract and release most of it in the ileal-colonic region. This approach places the product at the intersection of micronutrients, targeted delivery and microbiome modulation and illustrates how established nutritional ingredients can be repositioned through formulation science.

The concept also reflects a broader shift in the gut-health industry. Rather than introducing another bacterial strain or fermentate, manufacturers are beginning to explore whether vitamins and other familiar nutrients can be engineered to interact more directly with the microbial ecosystem.

Why the destination of vitamin B2 matters

B vitamins are central to microbial metabolism because they act as precursors of enzymatic cofactors involved in numerous cellular processes. Pathways associated with B-vitamin synthesis and utilisation are widely represented across gut microbial genomes, suggesting that these micronutrients contribute to the functioning of the intestinal ecosystem as well as to human physiology.

Riboflavin is particularly relevant because of its role in redox reactions and its antioxidant properties. According to the evidence summarised by dsm-firmenich, vitamin B2 may help protect intestinal cells and oxygen-sensitive microorganisms from oxidative stress. Colon-delivered riboflavin has also been associated with increased short-chain fatty acid production, greater microbial diversity and changes in taxa such as Blautia and Faecalibacterium prausnitzii.

The difficulty is that standard vitamin B2 formulations are not designed for microbial delivery. At recommended intake levels, riboflavin is predominantly taken up in the small intestine. This is effective when the objective is to meet the host’s nutritional requirements, but less suitable when the intended target is the colonic microbiota.

Historically, researchers have attempted to overcome this limitation by administering relatively high doses. Clinical studies using 50 or 100 mg of riboflavin per day have reported increases in acetate or butyrate, changes in microbial network organisation and, in some settings, shifts in potentially beneficial or undesirable bacterial groups. However, the use of high doses is a relatively blunt way of increasing colonic exposure. Targeted delivery offers an alternative strategy: protecting the nutrient during transit rather than simply supplying more of it.

A dual-trigger delivery system

Humiome B2 is produced as a multi-unit pellet system with different coating layers. The outer coating is pH-responsive and begins to dissolve during passage through the small intestine. An inner coating is designed to respond to microbial enzymes in the colon, releasing the riboflavin-containing core closer to the microbiota.

The company reports that approximately 90% of the vitamin B2 is released under ileal-colonic conditions, while around 10% is made available earlier in the digestive tract. By comparison, evidences estimates that only about 2% of conventional riboflavin reaches the gut microbiome.

The technology therefore combines two objectives. Most of the ingredient is directed towards the colon, while a smaller fraction remains available for conventional vitamin absorption. The formulation uses excipients from renewable resources and is described as microplastic-free and manufactured through a solvent-free process.

From a product development perspective, this is important because the innovation does not depend on discovering a new molecule. Instead, it changes the biological context in which a well established nutrient becomes available. The value proposition lies in delivery precision, local exposure and the possibility of generating microbiome related effects without relying on substantial riboflavin overdosing.

Building an evidence ladder

The scientific package supporting the ingredient includes fermentation experiments, simulated gastrointestinal models and human studies of riboflavin supplementation. These different levels of evidence should not be regarded as interchangeable, but together they provide a rationale for the targeted delivery approach.

In the TIM-1 and TIM-2 intestinal models, riboflavin loaded pellets remained largely intact during simulated upper gastrointestinal transit, with approximately 90% of the active ingredient subsequently released under simulated ileal-colonic conditions. The TIM-2 experiment also reported increased production of acetate and butyrate.

Additional fermentation studies found that riboflavin, alone or in antioxidant combinations, could increase microbial diversity, short-chain fatty acid production and the abundance of some butyrate-producing bacteria. Unpublished company experiments also suggest potential compatibility with commonly used probiotic strains, including Lacticaseibacillus rhamnosus GG, Bacillus coagulans BC30 and Bifidobacterium animalis subsp. lactis.

Human research provides further context. Earlier studies based on high oral doses reported increases in F. prausnitzii and Roseburia, reductions in Enterobacteriaceae in some populations and changes in markers of microbial metabolic activity. A four-week study using colon delivered riboflavin at 75 mg per day found increased alpha diversity and relative species abundance.

The evidences also refer to a 12-week dose-ranging study in older adults, currently described as under review, which evaluated colon-delivered doses of 1.4, 10 and 75 mg per day. According to the company summary, the intervention produced dose-dependent changes in diversity, butyrate production, keystone species and overall ecosystem performance. Because these results have not yet completed peer-reviewed publication, they should be interpreted as emerging rather than definitive evidence.

From “vitamin” to “biotic vitamin”

For the nutraceutical industry, the most significant aspect of Humiome B2 may be its category positioning. Dsm-firmenich describes the ingredient as a “biotic vitamin”, a term intended to communicate that the nutrient has been formulated specifically to interact with the gut microbiome.

This is primarily an innovation and commercial descriptor rather than a universally established scientific or regulatory category. Nevertheless, it could help manufacturers develop products that sit between conventional vitamin supplements and more familiar microbiome solutions such as probiotics, prebiotics, synbiotics and postbiotics.

The platform could be particularly relevant for combination products. Unlike a standalone probiotic, colon-targeted B2 is positioned as a substrate or metabolic support component that may be combined with microorganisms or microbial preparations. This creates opportunities for formulations in which the vitamin is not simply added for a nutritional claim, but selected to support the activity or resilience of the broader microbial ecosystem.

For ingredient suppliers and finished-product companies, that opens several possible territories: digestive health, healthy ageing, recovery after antibiotic exposure, gut-brain-axis products and multi-ingredient formulations designed around microbial function.

Early commercial translation

The concept has already moved beyond the research stage. In Poland, Humiome B2 is included in Lactinova Stress, a product launched by Hexanova in 2025 and positioned around the gut-brain axis. The formulation combines the colon-targeted vitamin with probiotics and prebiotics and is distributed through medically oriented channels, including pharmacies and hospitals.

Dsm-firmenich also describes additional products under development for Denmark and Germany.

These projects indicate how the ingredient may be used commercially: not as a replacement for existing biotic categories, but as an additional formulation component capable of differentiating combined products.

The business case is supported by growing consumer familiarity with the connection between digestive health and overall well-being. Dsm-firmenich cites market estimates forecasting biotic-ingredient growth of 4.5% in Europe and 6.6% in the Middle East and Africa between 2024 and 2030. Within an increasingly crowded market, targeted release, compatibility with other biotics and a recognisable micronutrient identity may offer manufacturers a more accessible innovation story than entirely novel microbial technologies.

Scientific potential must be matched by claims discipline

The commercial opportunity nevertheless requires careful communication. Evidence that a nutrient reaches the colon or modifies fermentation outcomes does not automatically translate into an authorised consumer health claim. The term “biotic vitamin”, microbiome-related messaging and any statements regarding specific health outcomes must be assessed against the regulations of each market and the characteristics of the finished formulation.

Dsm-firmenich also emphasises that regional requirements must be considered when labelling or advertising finished products and that manufacturers remain responsible for formulation suitability, stability and regulatory compliance.

This distinction will be central to the success of the category. The strongest near-term positioning may be based on targeted delivery, formulation innovation and microbiome-supporting mechanisms, while more specific health benefits will depend on the accumulation of peer-reviewed clinical evidence.

A platform for microbiome-targeted micronutrients

Humiome B2 illustrates a potentially important direction for microbiome product development. The industry has spent much of the past decade identifying new strains, microbial metabolites and fermentable substrates. Targeted micronutrients introduce another possibility: using delivery technology to reposition established compounds within the gastrointestinal tract.

In this model, the innovation is not simply vitamin B2. It is the combination of a familiar nutrient, a defined biological target and a delivery system capable of bringing the two together.

Whether “biotic vitamins” develop into a recognised market segment will depend on clinical validation, regulatory clarity and successful finished-product launches. But the underlying principle is likely to extend beyond riboflavin. As microbiome science becomes increasingly focused on microbial function rather than the presence of individual organisms, precisely delivered nutrients could become valuable tools for designing the next generation of gut-health products.